# DOCS — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-17. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 5.8 · Fundamentals 7.5 · Technicals 5.2 · Growth 6 · Risk 7

## Summary

Doximity is a high-quality digital health platform (89% gross margin, 30% net margin, net cash, ~$255M FCF) that has been cut in half from its 52-week high of $76.51 to $22.21, now trading at ~14x forward EPS with 15.5% short interest and earnings ~20 days out. The setup is a mean-reversion candidate off the base near $20, but Q4 FY26 revenue/margin step-down (op margin collapsing from ~38% to ~17% Q/Q, EPS Q/Q -68%) and a deteriorating tape argue for a small, disciplined position, not a hero trade into the August 6 print.

## Price targets (12-month horizon)

- Bear: $17.50
- Base: $26.00
- Bull: $34.00

## News context

Signal: the July 15 Stanford/Harvard NOHARM benchmark result showing Doximity Ask beat OpenEvidence and frontier models on clinical AI safety is a legitimate product differentiator in the healthcare AI narrative, and management has scheduled the FY27 Q1 print for August 6 after close — the real catalyst. Noise: the Zacks/Yahoo daily-move recap and the 'Winners and Losers of Q1' round-up are backward-looking. Broader-market items (crypto prediction markets, CLARITY Act, unrelated M&A) are irrelevant to DOCS. Social sentiment is dominated by pump-group spam and a reminder about a $31M securities-class-action settlement claim deadline — the settlement itself is already known and priced in, but it underscores the 2021-2023 disclosure overhang.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/docs-ai-stock-forecast-fa261ceb666333dff6241edf4d70edda
- AI-generated; model outputs can be wrong. Not financial advice.